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Abstract 
Huntington disease (HD) is an inherited neurodegenerative disorder caused by expansion of CAG 
repeats in the huntingtin gene, affecting initially the striatum and progressively the cortex.  
Oxidative stress, and consequent protein oxidation, has been described as important to disease 
progression. This review focuses on recent advances in the field, with a particular emphasis on 
the identified target proteins and the role that their oxidation has or might have in the 
pathophysiology of HD. Oxidation and the resulting inactivation and/or degradation of important 
proteins can explain the impairment of several metabolic pathways in HD. Oxidation of enzymes 
involved in ATP synthesis can account for the energy deficiency observed. Impairment of protein 
folding and degradation can be due to oxidation of several heat shock proteins and Valosin-
containing protein. Oxidation of two enzymes involved in the vitamin B6 metabolism could result 
in decreased availability of pyridoxal phosphate, which is a necessary cofactor in 
transaminations, the kynurenine pathway and the synthesis of glutathione, GABA, dopamine and 
serotonin, all of which have a key role in HD pathology. In addition, protein oxidation often 
contributes to oxidative stress, aggravating the molecular damage inside the cell. 
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Introduction 
Huntington disease (HD) is a dominantly inherited neurodegenerative disorder characterized by 
progressive degeneration of neurons in the striatum and, to a lesser extent, in the cerebral cortex. 
Clinical symptoms include psychiatric and cognitive abnormality, as well as involuntary 
movements and postures (chorea, dyskinesia and dystonia) of the legs, trunk and face. With the 
progression of the disease, motor rigidity and dementia predominate. HD usually manifests in 
midlife, develops over 15-20 years, and inevitably leads to death. The disease was first described 
by George Huntington as a hereditary disease under the name of chorea (from the Greek 
“choreia”, a dance, because of the involuntary movement of extremities). In 1993 it was 
discovered that the disorder involves an expansion of CAG trinucleotide repeats in exon 1 of the 
huntingtin (htt) gene, leading to an elongated polyglutamine sequence (polyQ) at the N-terminal 
of the huntingtin (Htt) protein [1]. HD appears when the number of glutamines expands beyond 
40. It is known that age of onset and severity correlate with the length of expansion [2]. Pre-
symptomatic patients present a significant atrophy of the caudate and putamen [3], suggesting 
that neurodegenerative events begin years before the occurrence of clinical symptoms. HD is 
accompanied by marked neuronal loss and proliferation of astrocytes expressing glial fibrillary 
acidic protein (GFAP) [4].  
Although Htt is a widely expressed 350-kDa protein, its physiological function remains 
unknown. It has antiapoptotic properties, a role in vesicle trafficking and the endosome/lysosome 
pathways and, in cortical cells, indirectly regulates the expression of brain-derived neurotrophic 
factor (BDNF), a prosurvival factor for striatal neurons. It is well known that the presence of 
mutant Htt (mHtt) results in the formation of both intranuclear and cytoplasmic ubiquitinated 
aggregates containing the protease-resistant mutated N-terminal Htt fragment in neurons of 
affected areas. There is recent controversy about whether protein aggregation directly impairs the 
ubiquitin-proteasome system activity, resulting in increased production of aggregated proteins [5]. 
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Even though aggregates often correlate with toxicity [6], polyQ proteins can also be toxic in the 
absence of detectable aggregates formation [7]. Recent evidences indicate that soluble oligomers 
can be more important than insoluble aggregates in HD pathogenesis [8-11]. Three factors are 
key to understanding the pathogenesis of HD: i) excitotoxicity, in which striatal neurons show 
increased sensitivity to glutamatergic activation by N-methyl-D-aspartate receptors (NMDARs), 
leading to excitotoxic neurodegeneration [12]; ii) impaired energy metabolism; and iii) oxidative 
stress. This review focuses on protein oxidative damage and its consequences, such as impaired 
energy metabolism, protein folding and pyridoxal-5 phosphate metabolism. 
 
1. Oxidative stress in Huntington disease 
The first signs of oxidative stress in brain areas affected by HD were described by several 
research groups in the eighties and nineties. It was reported that mitochondrial dysfunction was 
due to a decrease in several mitochondrial enzymes involved in respiration [13,14]. A first trial 
with -tocopherol, which reduces oxyradical damage to cell membranes, was performed in 1995 
in an attempt to slow down the course of HD [15]. Although d-alpha-tocopherol treatment had no 
effect on neurologic and neuropsychiatric symptoms for overall group, a significant therapeutic 
effect on neurologic symptoms was observed for patients early in the course of the disorder. 
The evidence of oxidative stress in HD has been exponentially growing since then. Many 
research groups have described impairment in mitochondrial ATP generation, leading to an 
energy defect in humans and in several HD models [16-20]. Complex II and III of oxidative 
phosphorylation (OXPHOS) seem to be the most affected, with complex IV having a milder 
defect. Reduced activity of other enzymes involved in oxidative metabolism, such as pyruvate 
dehydrogenase, has also been reported in affected areas of HD patients [21]. Similarly, loss of 
aconitase activity was reported in the caudate and putamen in symptomatic patients with 
caudate/putamen atrophy [17] and in the striatum in samples obtained postmortem [22]. It 
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remains to be determined whether these defects are a consequence of or play a pivotal role in 
striatal degeneration. 
Oxidative damage to DNA and lipids has also been reported to be increased in HD. The 
levels of 8-hydroxydeoxyguanosine (OH8dG), a product of oxidative damage, in nuclear DNA 
were significantly elevated in human HD [10,16] and in a mouse model [23]. Stable products of 
lipid peroxidation (e.g., F2-isoprostanes) are increased in HD cerebrospinal fluid [24]. In R6/1 
transgenic mice that express a human mutated htt exon 1, evidence of striatal lipid peroxidation 
has also been reported [25]. 
In addition to reactive oxygen species (ROS), reactive nitrogen species (RNS) seems to 
play a role in HD [26]; increased levels of 3-nytrotyrosine (3-NT) in cortex and striatium have 
been reported [16]. Activation of NMDA receptors results in Ca++ increase, which activates the 
neuronal form of nitric oxide synthase (nNOS). The nitric oxide generated can react to superoxide 
ions to generate peroxynitrite radical (ONOO-). Complexes of the mitochondrial electronic chains, 
and other mitochondrial enzymes like aconitase, are especially vulnerable to the effects of RNS. 
Thus, ROS and RNS act synergistically to increase the mitochondrial defect. However, although 
nitrosative stress has been involved in neuroinflammation and neurodegeneration in HD, nitric 
oxide can also have a cytoprotective role [27]. 
In HD, the initial cause of increased oxidative insult is the presence of mHtt, which has been 
shown to increase levels of ROS in neuronal and non-neuronal cells [6]. Aggregation of a 
fragment of mHtt directly causes free radical production [28] and inclusion bodies may act as iron-
dependent centers of oxidative stress [29]. Iron disorder described in HD would exacerbate such 
a stress situation [30]. Impairment of mitochondrial metabolism would increase the generation of 
ROS in the respiratory chain, the main intracellular source of ROS. In HD, microglia 
overactivation and dysregulation correlates with disease severity [31] and involves NADPH 
oxidase, the primary source of extracellular ROS production. Intracellular ROS have been found 
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to act as second messengers to amplify the proinflammatory function of microglia-mediated 
neurotoxicity [32]. Clearly, oxidative stress due to mHtt would result in a vicious circle aggravating 
the evolution of the disease.  
 
2. Vulnerability of the nervous system to oxidative stress 
What makes the nervous system especially susceptible to oxidative stress? Possible 
explanations include i) its oxidative metabolism, with a high oxygen consumption rate and strong 
dependence on aerobic carbohydrate metabolism; ii) the relatively low levels of antioxidant 
pathways and the fact that they decrease during aging, which explains, in part, the existence of 
several age-related neurodegenerative diseases; iii) the high polyunsaturated fatty acids content 
of the membranes, which makes them more susceptible to oxidative damage [33]; and iv) the fact 
that neurons are postmitotic and therefore damaged macromolecules that cannot be repaired or 
degraded would accumulate progressively inside the cells. However, oxidative stress plays a role 
in many neurological diseases. Why is the striatum the main target area in HD? Although the 
molecular mechanism leading to HD pathogenesis remains unknown, two factors probably play a 
key role: excitotoxic neurodegeneration due to glutamatergic NMDARs activation [12] and 
increased sensitivity to oxidative stress. In the context of the present review, it is important to 
understand why striatum is less resistant to the oxidative burst and its consequences. 
It is known that acute poisoning with mitochondrial toxins (cyanide, sodium azide, and 3-
nitropropionic acid) is often associated with striatal degeneration in humans and in laboratory 
animals [34]. Mitochondrial defects of genetic origins (e.g., mutation or deletion of mitochondrial 
DNA or nuclear DNA) can lead to striatal degeneration [35]. In the conditional mouse model 
Tet/HD94 that expresses a mutated Htt fragment selectively in the forebrain under the tet-
regulatable system [36], levels of catalase activity were decreased by 50% in the striatum, 
compared to cerebellum, of 20-month-old mice [37]. This supports the observation that at 20 
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months the mouse striatum presented lower levels of protein carbonylation compared to cortex 
and cerebellum. This suggests less endogenous ROS generation in the striatum, which would 
result in decreased antioxidant capacity. In this context, striatum in young rats has been shown to 
display decreased superoxide dismutase, catalase and glutathione peroxidase activities, and 
lower levels of glutathione (GSH) compared to cortex or other brain areas [38]. 
 
3. Protein oxidation in HD 
Under oxidative stress conditions, proteins undergo a series of structural modifications that in 
many cases result in loss of function. One well-documented protein alteration resulting from 
oxidative stress is carbonyl formation. It is used as a marker of protein oxidation because it is a 
major oxidative modification and can be easily detected and quantified by Western blot with anti-
dinitrophenyl (DNP) antibodies [39-41], a technique variously referred to as oxy-blot, carbonyl 
immunoblot or oxyproteome (when proteins are previously separated by 2D). Protein carbonyl 
derivatives are the result of oxidation of some amino acid side-chains, including arginine, proline, 
lysine, and threonine residues. Carbonyl derivatives can also be formed by secondary reactions 
with reactive carbonyl compounds on lipid peroxidation products, such as hydroxynonenal (HNE), 
and by glycation and glycoxidation reactions [42]. Several studies published more than 10 years 
ago reported increased protein carbonylation in HD in comparison to control samples [16,23,43]. 
In addition, carbonylated proteins and oxidative stress are correlated with disease stage [44], 
suggesting that oxidative stress may play an important role in the pathogenesis of HD. 
Despite all these observations, only a few studies have been designed specifically to 
identify target proteins. The first report was published by the Butterfield group using the R6/2 
transgenic mice model [45]. In samples from striatum of HD patients, our laboratory extensively 
studied and identified carbonylated proteins in comparison to samples from control cases [22,37]. 
Oxidation of the mHtt protein has also been reported [11]. From these studies one can classify 
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the damaged proteins in several groups: those involved in energy metabolism, in folding and 
oxidative stress defense, in vitamin B6 metabolism, and a miscellaneous group of unrelated 
proteins (Table 1). 
 
3.1. Proteins involved in energy metabolism 
As described above, besides mHtt aggregation, energetic dysfunction was one of the first traits 
described in HD. Different enzymes, mainly mitochondrial ones involved in ATP generation 
pathways, have been described to present decreased activity in human HD samples or HD 
models. However, whether this is the result of decreased gene transcription, protein degradation 
or enzyme inactivation remains to be established. Nevertheless, several proteins from this group 
are known to suffer carbonyl formation, either in humans and/or the transgenic R6/2 mouse tissue 
samples. Three are members of the glycolytic pathway: enolase, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and pyruvate kinase. Perluigi et al. [45] found that carbonylation of  
and enolase in R6/2 mice resulted in their inactivation, while our group did not find significant 
differences in GAPDH or pyruvate kinase activity in postmortem human samples [37].  
Five mitochondrial proteins involved in energy metabolism were also carbonylated. Two 
are enzymes of the Krebs cycle (citrate synthase and aconitase), two are members of the 
OXPHOS (subunit 2 of cytochrome b-c1 -complex III- and the alpha subunit of ATP synthase), 
and the fifth is mitochondrial creatine kinase. Oxidation resulted in enzyme inactivation, with a 
remaining activity of ATP synthase and creatine kinase below 50%, compared to controls. 
Mitochondrial aconitase is an iron-sulfur protein that catalyzes the stereospecific isomerization of 
citrate to isocitrate via cis-aconitate. It shows a particular susceptibility to oxidative damage due 
to release of iron ions from its iron-sulfur cluster in the active center [46]. Therefore, due to the 
effects of iron as a superoxide generator, inactivation of aconitase can initiate a cascade with the 
potential to cause a dramatic increase in the cellular burden of oxidative damage.  
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The key role of mitochondrial impairment in HD is highlighted with two chemical models 
of HD using inhibitors of succinate dehydrogenase (complex II): 3-nitropropionic acid (3-NP) and 
malonate. Mice treated with the irreversible inhibitor 3-NP have striatal lesions, exhibit choreiform 
and dystonic movements, and demonstrate cognitive deficits, all similar to HD [47]. Interestingly, 
increased oxidative stress was evident prior to the appearance of morphological lesion, and 
protein oxidation in striatal synaptosomes precedes 3-NP-induced striatal lesion formation [48]. 
Mice treated with the reversible inhibitor malonate are also used as a chemical model [49]. Both 
3-NP and malonate produce energy depletion and lesions that closely resemble those of HD. 
In human HD striatum, creatine kinase activity decreased by 65% [37]. The observed 
carbonylation and inactivation of mitochondrial creatine kinase in human HD compared to 
controls was also detected in a murine model [45]. The two creatine kinase isoforms (cytosolic 
and mitochondrial) phosphorylate creatine; this molecule constitutes the most important energy 
buffering and transport system of the cell, especially in muscle and neuronal tissue [50]. 
Mitochondrial creatine kinase is located in the intermembrane space and the phosphocreatine 
produced is then transported to the cytosol [51]. Creatine therapy provides neuroprotection and 
delays motor symptoms in a transgenic animal model of HD [52,53], thus suggesting enhanced 
cerebral energy metabolism as a protective mechanism against neurodegeneration. However, 
this neuroprotective effect could not be replicated in clinical trials, in which the treatment period 
may have been too short and concentrations too low [54;55]. Nevertheless, creatine 
supplementation lowers glutamate levels in humans, indicating a therapeutic potential in HD [55]. 
The huge quantity of information obtained concerning the protective role of creatine in HD models 
has led to a reassessment of the possible therapeutic value of higher doses of creatine. Phase III 
clinical trials are ongoing to evaluate treatments with 40 g creatine/day (clinicaltrials.gov). 
Taken together, these results are in agreement with the profound impairment of 
mitochondrial bioenergetic pathways described in HD, which produces severe ATP depletion and 
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increased lactate levels [56,57]. In HD patients and mouse models alike, increased lactate 
concentrations in the cerebrospinal fluid, elevated blood glucose levels and defects in 
mitochondrial complexes II, III and IV have been consistently described [58]. Thus, similar to what 
has been described in Parkinson disease [59], oxidative modifications in HD that result in 
mitochondrial dysfunction will increase ROS generation and secondary excitotoxicity. In this 
context, and like in the case of creatine, although initial trials with the antioxidant idebenone (a 
synthetic analog of coenzyme Q10) did not show significant differences between groups [60], 
treatments with higher doses (2400 mg/day) are now in phase III clinical trials (clinicaltrials.gov). 
 
3.2. Proteins involved in oxidative stress defense and protein folding 
Many neurodegenerative diseases including Alzheimer, Parkinson and polyQ diseases are 
thought to be caused by protein misfolding. In HD, molecular chaperones are recruited by the 
aggregated mHtt as abnormally folded; thus mHtt may reduce the availability of HSPs, increasing 
protein aggregation. In this context, the protective role of molecular chaperones in HD is well 
known [61]. Against this backdrop, carbonylation of three chaperones has been published: Hsp90 
from R6/2 mice and, from human striatum, Hsc71 (a member of the Hsp70 family) and T complex 
protein 1 subunit beta (a chaperonin-containing t-complex peptide 1 -TCP1-) (Table 1). Oxidation 
could impair their chaperone activity. As a consequence, increased polyQ oligomerization and 
aggregation would decrease mHtt degradation, exacerbating the symptoms. The role of the 
Hsp70 family has been well studied in HD. In mouse models, loss of Hsp70 aggravates 
pathogenesis [62], while its induction reduces changes in striatal electrical activity [63]. Moreover, 
Hsp70/Hsc70 can reduce polyQ toxicity and aggregation in a cellular model of HD [64]. TCP1, 
also called TRiC (TCP-1 ring complex), assists protein folding upon ATP hydrolysis, acting 
downstream of Hsp70 and Hsp40. In the HD context, TRiC involvement has been shown to 
prevent polyQ aggregation and may have an early role hindering Htt access to pathogenic 
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conformations [65]. There is much evidence that elevated levels of protein chaperones suppress 
polyQ protein misfolding. Heat shock transcription factor 1-activating compounds, the main 
regulator of the heat shock response, markedly suppress neurodegeneration in several HD 
models [66,67]. Thus, activation of the heat shock response appears to be an attractive 
therapeutic target. 
In human brain affected by HD, antioxidant defense proteins were strongly induced in 
striatum, but also detectable in cortex [22]. Among them, peroxiredoxins (Prxs) exerted their 
antioxidant role in cells through their peroxidase activity whereby H2O2, peroxynitrite, and a wide 
range of organic hydroperoxides are reduced and detoxified. Prx1 and Prx6 have been described 
to be primarily expressed in astrocytes and microglia [68]. The presence of higher amounts is due 
to astrocyte proliferation and/or increased gene expression as a consequence of microglia 
activation. Prx1 and Prx6 are present in a 2D gel electrophoresis as two spots [22]; one of them 
can be hypothesized to be an oxidized form of the enzyme. This assumption is based on the fact 
that in lens cells under oxidative stress, Prx1 show a specific oxidation of the active site residue 
Cys52 to cysteic acid, which produces an acidic pI shift. [69]. Even though no specific analysis 
has yet been conducted, one can speculate that in HD the more basic spot detected in the Prx1 
immunostain would be the unmodified form of Prx1 and the more acidic would be the oxidized 
form of Prx1. A similar trend is observed in Prx6, which also appeared as two spots with a similar 
pI shift. In fact, Prx1 and 6 are homologous proteins, and both Prxs have a highly conserved Cys 
at the active site (Cys44 in Prx6). Oxidation of these key residues would lead to enzyme 
inactivation that in turn would worsen the oxidant burst. 
 
3.3 Vitamin B6 metabolism 
Two enzymes, pyridoxal kinase (PDXK) and antiquitin 1 (-aminoadipic semialdehyde 
dehydrogenase or ALDH7A1), involved in the metabolism of pyridoxal 5-phosphate (PLP), the 
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active form of vitamin B6 were identified from the proteomic analysis of carbonylated proteins in 
human HD [37]. PDXK is responsible for pyridoxal phosphorylation, resulting in activation of 
vitamin B6, and can also phosphorylate both pyridoxine and pyridoxamine, which are converted 
to PLP through the oxidase PNPOX [70] (Fig. 1). PLP is a necessary cofactor in more than 140 
distinct enzymatic activities. Whether PDXK oxidation results in enzyme inactivation is not known 
at present; however, in the same study [37], PDXK showed a 30% decrease in striatal HD 
samples compared to controls. This is not unusual, since it is known that protein oxidation labels 
proteins for degradation. Thus, PLP synthesis could be impaired both by the decrease in PDXK 
levels and by its oxidation. These results were also observed –with greater impact– in the 
Tet/HD94 conditional mouse model [37].  
In 2005, a rare disorder was identified with neonatal seizures and severe epileptic 
encephalopathy due to mutations in PNPOX [71]. The seizures typically involve irregular 
involuntary muscle contractions (myoclonus), abnormal eye movements, and convulsions. Most 
untreated patients died within a year of their birth. When treated, patients were unresponsive to 
anticonvulsants and pyridoxine, but responsive to PLP [72]. High doses of PLP have been very 
efficient in controlling seizures when given orally or via a nasogastric tube.  
Antiquitin 1 (ALDH7A1) acts as a D1-piperidine-6-carboxylate (P6C) dehydrogenase. The 
role of antiquitin 1 in PLP metabolism was known because mutations in the ALDH7A1 gene 
cause pyridoxine-dependent seizures, a disease affecting newborns and children. In these cases, 
mutations abolish antiquitin 1 activity and the accumulating substrate -P6C- inactivates PLP by 
forming a Knoevenagel condensation product [73]. The lack of PLP causes seizures and is 
associated with learning difficulties. These seizures are fully controlled by pyridoxine [74]. Thus, 
antiquitin 1 oxidation observed in human HD could result in its inactivation, exacerbating the lack 
of PLP available as a cofactor. 
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From these results we hypothesized that decreased PLP levels, caused by impairment of 
its synthesis and inactivation by P6C, would have severe consequences in the affected areas: i) 
enzymes involved in the synthesis of neurotransmitters like GABA, dopamine, and serotonin 
require PLP for this activity; ii) all transaminases would be affected, including those found in the 
kynurenine pathway and those using glutamate as a substrate/product; and iii) synthesis of 
glutathione from homocysteine involves two PLP-dependent enzymes (Fig. 1). 
In HD, striatal neurodegeneration is reflected by intrinsic neurons deficiency in the 
neurotransmitters, particularly in GABA. In postmortem HD studies, the concentration of this 
neurotransmitter in HD is reduced to less than one-third of normal values in the striatum [75], with 
deficits exceeding 25% in the cortex [76]. Similarly, in the R6/2 mouse model, striatum-specific 
lower concentrations of GABA were also found [77]. In an attempt to increase GABA-mediated 
neurotransmission, five patients with HD were given L-glutamate (the substrate for glutamic acid 
decarboxylase) and pyridoxine for 2 years; no improvement of motor and behavioral function was 
detected [78]. In the light of our results, pyridoxine administration would not be efficiently 
converted to PLP due to pyridoxal kinase deficiency. As a consequence of decreased PLP 
availability, glutamate decarboxylase would not be able to produce GABA from glutamate.  
Glutamate decarboxylase impairment related to lack of PLP would also result in 
increased levels of glutamate. The excitotoxic model of HD proposes a relative excess of 
glutamate as the mechanism for cell death in HD, especially in the striatum. In this context, the 
combined glutamate and glutamine concentration has been found to be elevated in the striatum 
of HD patients [79]. In R6/2 mice, a profound metabolic alteration in glutamate/glutamine cycling 
was found in different brain areas, including the striatum [80]. 
In addition to glutamatergic stimulation from the cortex, the striatum is the predominant 
target of dopaminergic neurons that originate from the substantia nigra [81]. Lack of PLP would 
result in DOPA decarboxylase impairment, leading to decreased dopamine levels. Recent reports 
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demonstrate that impaired dopamine release in HD mice models contribute to progressive motor 
phenotype [82], and striatal dopamine levels are decreased in the striatum of R6/2 mice [83]. 
However, the relative overactivity of the dopaminergic system also seems to be a major cause of 
involuntary movements in HD. Thus, the pattern of cerebral dopamine abnormalities in HD is 
complex, evidenced by the variable clinical benefit of both dopamine antagonists [84] and 
agonists [85] in treating HD symptoms. 
Depression is the most common psychiatric disorder in HD patients, and in the general 
population, serotoninergic dysregulation might be related to develop depression. As shown in Fig. 
1, serotonin synthesis would also be affected by PLP deficiency. Although serotonin metabolism 
has been little characterized in human HD, it is interesting to note that in R6/2 mice, serotonin 
levels are significantly decreased [83]. 
Lower levels of PLP would also affect GSH synthesis and, as a consequence, the entire 
GSH-dependent antioxidant defense system. However, published results are not conclusive. In 
HD patients, lower levels of reduced GSH were detected both in plasma [86] and in red blood 
cells [87]. Nevertheless, increased total glutathione levels (GSH+GSSG) were observed in 
cortical and striatal mitochondria of the R6/2 mice [88], and the physiologically relevant 
GSH/GSSG ratio has not been measured. 
In HD, alterations in the kynurenine pathway have largely been demonstrated [89,90]. In 
this pathway, the enzyme kynurenine aminotransferase (KYNT), catalyzes the conversion of 
kynurenine to kynurenic acid, the latter having a neuroprotective effect through modulation of the 
mitochondrial function [91]. A reduced kynurenic acid:kynurenine ratio has been reported in HD, 
suggesting a decreased activity of kynurenine aminotransferase [92]. Like all aminotransferases, 
this enzyme is PLP-dependent, so impaired activity due to a PLP deficit would explain this 
decreased activity (Fig. 1). As a consequence of increased kynurenine levels, the presence of 
both 3-hydroxykynurenine (3-HK), a free radical generator, and quinolinic acid (QUIN), would 
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increase. This has been demonstrated in mouse models of HD and humans [93;94]. Intrastriatal 
administration of QUIN, an agonist of NMDARs, selectively affects the GABAergic neurons in a 
mouse model [95]. This produces a phenotype similar to that observed in human HD, and for that 
reason QUIN treatment is used as a chemical model of HD. In model systems either in vitro or in 
vivo, 3-HK and QUIN have been shown to cause neurodegeneration via a combination of 
excitotoxic mechanisms and oxidative stress [96]. Thus, the shift away from the synthesis of 
kynurenic acid and towards the formation of 3-HK and QUIN may be important in the pathology of 
HD. In this context, inhibition of the enzyme kynurenine 3-monooxygenase (KMO), which 
catalyzes conversion of kynurenine to 3-HK, would shift the flux in the pathway towards the 
formation of kynurenic acid. Thus, KMO has been recently used as a target of pharmacological 
inactivation therapy in mouse models [89;97]. 
 
3.4. Mutant Huntingtin 
MHtt protein is cleaved into a number of polyQ-containing N-terminal fragments that misfold and 
form soluble monomeric and oligomeric proteins as well as insoluble aggregates [8]. Oxidative 
stimuli enhance the polyQ-expanded truncated N-terminal Htt, also called N171 [98]. N171 Htt 
interacts with and chemically reduces copper (II) [99]. Recently, it has been reported that copper 
binding promotes oligomerization, modulating the N-terminal Htt structure [11]. These 
noncovalently cross-linked oligomeric forms are finally remodeled by oxidation of Cys115 and/or 
Cys119, which then form intermolecular disulfides. More important, the authors showed slower 
clearance of oxidizable N171 Htt from the soluble cell fraction, indicating that modulation of the 
Htt oxidation state can alter soluble mHtt levels in HD. This is especially relevant since several 
publications have shown that soluble N-terminal fragments of mHtt or amyloid-like aggregates, at 
levels of aggregation that precede inclusion body formation, might exert toxicity [100,101]. Thus, 
after Cys oxidation, N-terminal fragments from mHtt are more prone to form soluble oligomeric 
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species that are potentially more toxic than aggregates or inclusion bodies. This idea may also 
apply to other neurodegenerative diseases, where there is evidence that soluble oligomers may 
be particularly important for toxicity [100;102]. 
 
3.5 Glial Fibrillary Acidic Protein 
In HD, proliferation of astrocytes results in increased levels of GFAP, a class-III intermediate 
filament [4]. By proteomic analysis, GFAP appeared as one of the main carbonylated proteins, 
especially in HD striatum [22]. Because the increased carbonyl levels of GFAP presented in HD 
could reflect the increased amount of protein present, a deeper analysis of the GFAP 
carbonylation was performed using narrow immobilized pH gradient strip [22]. In a 2D gel, GFAP 
appeared in more than 20 spots with different Mw (from 35 to 50 kDa) and isoelectric points (from 
4 to 5.5). When GFAP carbonylation and protein expression were normalized, it was inferred that, 
on average, GFAP was approximately twice as oxidized in striatum from HD patients than in that 
of matched controls. In the cortex, differences between HD and controls were not clear. However, 
specific carbonylation of some of the multiple existing isoforms cannot be ruled out. It is worth 
mentioning that GFAP has been identified as a major target of oxidative damage in Pick disease 
[103], Alzheimer disease [104] and aceruloplasminemia brain [105]. Whether this elevated 
sensitivity to oxidation is associated with loss of function and the potential consequences for cell 
physiology remains to be answered.  
 
3.6 Transitional endoplasmic reticulum ATPase 
Transitional endoplasmic reticulum ATPase, also known as valosin-containing protein (VCP), is a 
member of the AAA family of ATPases associated with several cellular activities. Mutations in 
VCP cause inclusion body myopathy (IBM), Paget disease of the bone, and frontotemporal 
dementia (IBMPFD). The role of VCP in autophagy has been demonstrated in IBMPFD, and 
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impaired autophagy due to VCP dysfunction explains the pathology seen in this disease, 
including abnormal TDP-43 (a DNA-binding protein) accumulation in neuronal and muscle 
inclusions [106]. In HD, VCP colocalizes with protein aggregates in neurons of HD patients and in 
cultured cells expressing diseased proteins [107]. TDP-43 also accumulates in the brain of HD 
cases, although the mechanism of this alteration is not known [108]. By proteomic analysis, VCP 
appears as an oxidatively modified protein in HD. Oxidative stress has been described to 
inactivate VCP ATPase activity [109]. Moreover, accumulation of protein aggregates might result 
in VCP dysfunction, causing impairment of the ubiquitin-dependent protein degradation, ER 
stress, oxidative stress and pathological involvement of mitochondria [110]. Thus, in HD, the 
observed VCP carbonylation in striatum may result in loss of its activity affecting the above 
mentioned processes, including autophagy, and may play a role in abnormal TDP-43 inclusions in 
HD.  
 
3.7 Dimethylarginine dimethylaminohydrolase 1 
Dimethylarginine dimethylaminohydrolase 1 (DDAH1) hydrolyzes both N(G),N(G)-dimethyl-L-
arginine (ADMA) and N(G)-monomethyl-L-arginine, both of which act as inhibitors of NOS. 
DDAH1 has, therefore, a role in nitric oxide generation. DDAH1 is highly resistant to high doses 
of H2O2 but is inhibited upon specific Cys-S-nitrosylation by S-nitroso-L-homocysteine [111]. 
Moreover, L-homocysteine inhibits DDAH1 activity by reacting with one Cys at the active site 
[112], causing ADMA accumulation and decreasing nitric oxide production and bioavailability. 
DDAH1 is also inhibited by pathophysiologic concentrations of the lipid peroxidation product 4-
HNE [113]. The mechanism of inhibition is related to the formation of Michael adducts on a 
catalytic His. 
In general, it is accepted that nitric oxide might play a toxic role in HD; however, the exact 
function is still uncertain. In R6/1 mice, NOS expression was increased at 19 weeks, followed by 
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a decreased level in 35-week-old mice, compared with controls, a phenomenon that parallels the 
changes in NOS enzyme activity [114]. This seems to indicate that, at least in R6/1 mice, nitric 
oxide is involved in the onset of the progressive neurological phenotype, but its role can change 
at different stages of the disease. Perhaps oxidation of DDAH1 found in human HD post-mortem 
samples, which could negatively affect nNOS activity, resembles the final stage of the disease in 
the transgenic mice. 
 
3.8 Voltage-dependent anion channel 1 
The voltage-dependent anion channel 1 (VDAC1) located in the outer mitochondrial membrane 
acts as a gatekeeper for the entry and exit of mitochondrial metabolites. VDAC, together with the 
ADP/ATP translocase and cyclophilin-D, form the mitochondrial permeability transition pore (PTP) 
allowing cross-talk between mitochondria and the cytosol [115]. Carbonylation of VDAC was 
described in R6/2 transgenic mice compared to control littermates [45]. Although the effect of 
such oxidative modification was not explored, the authors suggested that impairment of VDAC1 
can explain the calcium overload and PTP-induced mitochondrial dysfunction observed in HD 
mouse models and human brain [116]. Also, VDAC oxidation might affect its functional properties, 
thus contributing to disruption of PTP permeability. This would lead to a lower Ca2+ threshold for 
depolarization, to a decreased membrane potential, and ultimately to alteration of mitochondrial 
permeability. Changes in cytochrome c release and apoptosis would be among the 
consequences. Consistent with this notion, cyclosporin A, an inhibitor of PTP, avoids the toxic 
effects of 3-NP in vivo and in vitro, presumably by blocking the pro-apoptotic release of 
cytochrome c [117].  
 
4. Selectivity of protein oxidation 
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An important aspect to consider is why the proteins listed in Table 1 are especially prone to suffer 
oxidative damage. What do all these identified targets have in common? The most important 
shared trait, which affects not all but most of them, is that they bind to molecules such as iron or 
nucleotides phosphate like ATP/ADP. Aconitase and cytochrome b-c1 (complex III) are proteins 
which bind iron directly or indirectly. Pyruvate kinase, citrate synthase, aconitase, cytochrome b-
c1 complex, ATP synthase, creatine kinase, Hsc71, TRiC, Hsp90, pyridoxal kinase and VCP are 
nucleotide-binding proteins. It should be kept in mind that all nucleotide phosphates like ATP and 
ADP have a coordinated magnesium ion. It has been proposed that under oxidative stress and 
iron overload, both observed in HD, nucleotide-binding proteins are specific targets of oxidative 
damage [41]. This sensitivity has been attributed to the ability of Fe(II) to replace magnesium ions 
bound to the phosphate groups of the nucleotides; their reaction with H2O2 or oxygen would then 
trigger the formation of ROS. As an example, oxidation of ATP synthase in vitro has been shown 
to be mediated by iron binding to magnesium-binding sites [118]. In this context, enzymes with a 
Fe-binding site or prosthetic groups with iron are especially prone to suffer oxidative damage 
[119]. It is well known that aconitase is especially sensitive to oxidative stress. Aconitase loses its 
Fe-S cluster under oxidative stress conditions and is carbonylated under different conditions and 
pathologies [46]. A similar situation could occur in the cytochrome b-c1, which has a heme-Fe 
group. In addition to binding to specific nucleotides, carbonylation of Hsc71, TRiC, and Hsp90 
also can be explained by their interaction with damaged proteins produced under oxidative stress. 
It has been suggested that oxidized proteins contain reactive species that can, in turn, damage 
other proteins [120].  
A second group of proteins (GAPDH, Prx1, Prx6, mHtt, DDAH1) seen as oxidized in HD 
presents highly reactive thiol -or His- groups at or near their active site. Such Cys have been 
described to be easily oxidizable, producing oxidized reversible forms of thiol, like inter/intra 
disulfides bonds in the case of mHtt, or irreversible forms like cysteic acid (also known as sulfonic 
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acid (Cys-SO3H) in the case of Prx1 and Prx6. DDAH1 also has a reactive Cys which has been 
described to be nitrosylated, but the presence of a carbonyl group in this protein can be due to 
reaction with HNE (Michael addition) on a catalytic His [113]. However, HNE is more prone to 
react to thiol groups [121] and because it is well known that GAPDH has a highly reactive Cys in 
its active site, HNE binding could explain its carbonylation. In two cases (enolase and VDAC1) 
their carbonylation remains to be explained, although oxidative modification of enolase has been 
described in several stress conditions [46]. 
 
5. Concluding remarks 
The existence of oxidative stress in affected areas of HD patients and animal models is widely 
assumed. Although it is not completely understood how mHtt causes this stress, a toxic gain of 
function is well accepted. It is clear that mHtt expression results in increased levels of oxidatively 
damaged proteins and other macromolecules in specific areas of the HD-affected brain. Fig. 2 
summarizes the altered functions and metabolic pathways affected by ROS production as a 
consequence of mHtt. Oxidation of some specific proteins would, in turn, increase the ROS 
levels. This produces a vicious cycle with a progressively increased stress situation that, in 
addition to the oxidation of several chaperones and decreased proteasomal function, might 
contribute to the accumulation of damaged proteins. An important question still under discussion 
is whether oxidative stress and its consequences, such as protein (but also DNA and lipid) 
damage, play a pivotal role in the pathogenesis of HD or are a secondary consequence of striatal 
degeneration. From our point of view, research results increasingly point to the important role of 
oxidation of some proteins, even in the early stages of the disease, particularly in impairment of 
energy production and protein folding. Although in past studies treatment with antioxidants failed 
to deliver clear benefits to HD patients, increased doses of coenzyme Q and creatine are 
currently under evaluation in phase III clinical trials. 
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Results from our group indicate a possible important role of vitamin B6 metabolism. 
Decreased levels of PLP would affect important pathways known to be altered in HD, including 
synthesis of several neurotransmitters, GSH and the kynurenine pathway. In this context, 
treatment with PLP, the active form of vitamin B6 (instead of pyridoxine or piridoxal), should be 
considered for evaluation as a therapy. 
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Table 1 
Protein targets of oxidative damage in HD  
 
Protein Source Observed modification Oxidation effect Reference 
Energy metabolism     
-Enolase  Human striatum R6/2 mouse 
Carbonylation 
Carbonylation 
Unknown 
Inactivation 
[37] 
[45] 
-Enolase (brain-specific isoform) Human striatum R6/2 mouse 
Carbonylation 
Carbonylation 
Unknown 
Inactivation 
[22] 
[45]  
Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) Human striatum Carbonylation No inactivation [37] 
Pyruvate kinase isoenzymes M1/M2 
(PK) Human striatum Carbonylation No inactivation [37] 
Citrate synthase, mitochondrial  (CS) Human striatum Carbonylation Inactivation [37] 
Aconitase Human striatum R6/2 mouse 
Carbonylation 
Carbonylation 
Inactivation 
Inactivation 
[22] 
[45] 
Cytochrome b-c1 complex subunit 2, 
mitochondrial Human striatum Carbonylation Unknown [37] 
ATP synthase subunit alpha Human striatum Carbonylation Inactivation [37] 
Creatine kinase Human striatum R6/2 mouse 
Carbonylation 
Carbonylation 
Inactivation 
Inactivation 
[22,37] 
[45] 
Oxidative stress defense and folding     
Heat shock cognate 71 kDa protein 
(Hsc71) Human striatum Carbonylation Unknown [37] 
T-complex protein 1 subunit beta 
(TCP1, TRIC) Human striatum Carbonylation Unknown [37] 
37 
 
Heat Shock Protein 90 (Hsp90) R6/2 mouse Carbonylation Unknown [45] 
Peroxiredoxin 1 (Prx1) Human striatum Acidic pI shift (putative cysteic acid formation) 
Unknown  
(putative inactivation) [22] 
Peroxiredoxin 6 (Prx6) Human striatum Acidic pI shift (putative cysteic acid formation) 
Unknown  
(putative inactivation) [22] 
Pyridoxal phosphate metabolism     
Pyridoxal kinase 
Human striatum 
 
Tet/HD94 mouse 
Carbonylation 
 
Carbonylation 
 
Unknown (putative 
degradation) 
Unknown (putative 
degradation) 
[37] 
Aminoadipic semialdehyde 
dehydrogenase (antiquitin 1) Human striatum Carbonylation Unknown [37] 
Miscellaneous     
Mutant Huntingtin CAG140 mice and PolyQ transfected COS cells Cys oxidation 
Intermolecular disulfides 
(stable olimerization) [11] 
Glial fibrillary acidic protein (GFAP) Human striatum Carbonylation Unknown [22] 
Transitional endoplasmic reticulum 
ATPase (VCP) Human striatum 
Carbonylation 
 Unknown [37] 
Voltage-dependent anion channel 1 
(VDAC) R6/2 mouse Carbonylation Unknown [45] 
N(G), N(G)-dimethylarginine 
dimethylaminohydrolase 1 (DDAH1) Human striatum Carbonylation Unknown [37] 
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Figure legends 
Fig. 1. Oxidation of pyridoxal kinase (PDXK) and antiquitin 1, involved in pyridoxal-5-phosphate 
(PLP) metabolism, may impair synthesis of neurotransmitters and glutathione (GSH). All 
aminotransferases and the kynurenine pathway would also be affected. CS, cystationine -
synthase, CL, cystationine -ligase; GAD, glutamate decarboxylase; 5-HTP, 5-hydroxytryptophan; 
5-HTP DC, 5-hydroxytryptophan decarboxylase; DOPA DC, dopamine decarboxylase; 3-HK, 3-
hydroxyquinurenine; KMO, kynurenine monooxigenase; KYNT, kynurenine transaminase; P6C, 
L--piperidine-6-carboxylate; PNPOX, pyridoxamine/pyridoxine 5-phosphate oxidase; QUIN, 
quinolinic acid; TH, tyrosine hydroxylase; TPH, tryptophan hydroxylase. 
Fig. 2. Oxidative damage of target proteins in HD might lead to dysfunction of multiple processes 
inside the cell. ADMA, dimethyl arginine; CK, creatine kinase; CS, citrate synthase; CS, 
cystationine -synthase, CL, cystationine -ligase; DDAH1, dimethylarginine 
dimethylaminohydrolase 1; DMA, dimethylamine; DOPA DC, dopamine decarboxylase; GAD, 
glutamate decarboxylase; GAPDH, glyceraldehyde 3-phosphate; dehydrogenase; GFAP, glial 
fibrillary acidic protein; Hsc71, heat shock cognate 71; Hsp90, heat shock protein 90; 3-HK, 3-
hydroxyquinurenine; 5-HTP DC, 5-hydroxytryptophan decarboxylase; KYNT, kynurenine 
transaminase; PDXK, pyridoxal kinase; nNOS, neuronal nitric oxide synthase; PK, pyruvate 
kinase; Prx1/6, peroxiredoxin 1/6; TRiC, TCP-1 ring complex; UPS, ubiquitin-proteasome system; 
VCP, valosin-containing protein. 
